JAK3 and lymphoma: Using this model we reveal a two-step mutational process reflecting disease progression, whereby an activating JAK3 mutation known to drive lymphoma formation is joined in progressed disease by novel inactivating mutations of SOCS1, thereby weakening the latter's inhibitory potency.